ArticleCommunications biology2026
Seesaw signatures capture trajectory-like transcriptomic shifts and enable compact tumour cell classification across cancers.
Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Seesaw signatures capture trajectory-like transcriptomic shifts and enable compact tumour cell classification across cancers.Communications biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Accurate identification of tumor cells remains a major challenge in single-cell cancer research because malignant and normal cells often differ only subtly and vary greatly across datasets. Here we show that Seesaw pairs, defined by consistent reversals in the relative expression ranks of gene pairs between normal and tumor cells, provide compact and informative markers of malignant transformation. Across 44 single-cell RNA sequencing datasets spanning 22 cancer types, a classifier based on just three Seesaw pairs achieves a median area under the receiver operating characteristic curve of 0.93 in independent test sets and outperforms CellTypist, CTISL, ikarus, and scMalignantFinder. Recurrent Seesaw pairs reveal shared cancer-associated programs across malignancies, and many associated genes are linked to poor prognosis in The Cancer Genome Atlas cohorts. Because the framework is simple and interpretable, it may facilitate practical low-dimensional assays and may also be extendable to other data types in which coordinated rank disruption is informative.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.